Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ATRA
SellHot AirAtara Biotherapeutics, Inc. · Healthcare · United States · $92M · Avg Vol: $511K/d
COMPANY DESCRIPTION
Atara Biotherapeutics, Inc. is a pioneer in allogeneic T-cell immunotherapy, developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions. The company competitive moat is established by its proprietary Epstein-Barr virus T-cell platform, which enables the creation of off-the-shelf, targeted immunotherapies like Ebvallo. It operates as a leading clinical-stage biotechnology player at the forefront of cellular medicine.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 63.6M | 8.6M | 128.9M | 120.8M | 23.9% | 6.2M | 2.8M | 40.9M | -41.8% |
| EPS | -23.85 | -30.81 | -11.41 | 2.61 | — | -1.54 | -0.95 | 1.55 | -23.1% |
| Shares | 9.0M | 9.0M | 5.9M | 7.3M | -18.7% | — | — | — | — |
| Debt | 71.7M | 57.9M | 43.8M | 10.4M | -47.5% | 9.9M | — | — | — |
| Equity | 126.6M | -99.2M | -97.3M | -38.5M | — | — | — | — | — |
| Op CF | -270.4M | -193.0M | -68.7M | -50.9M | — | -21.9M | — | — | — |
| Inv CF | 203.0M | 123.9M | 8.6M | 18.1M | — | — | — | — | — |
| Fin CF | 53.1M | 2.0M | 59.3M | 16.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc.(you) | $92M | 23 | Sell |
| ACET | Adicet Bio, Inc. | $85M | 22 | Sell |
| PTHS | Pelthos Therapeutics Inc. | $95M | 25 | Sell |
| ACRV | Acrivon Therapeutics, Inc. | $88M | 27 | Sell |
| MNOV | MediciNova, Inc. | $71M | 24 | Sell |
| LONA | LeonaBio, Inc. | $75M | 20 | Strong Sell |
| BDTX | Black Diamond Therapeutics, Inc. | $128M | 23 | Sell |
| SEER | Seer, Inc. | $110M | 28 | Sell |
| NRXS | NeurAxis, Inc. | $75M | 18 | Strong Sell |
| XBIT | XBiotech Inc. | $69M | 27 | Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.1%